

Efficacy and Safety of Topiramate for the Treatment of Double-Blind, Placebo-Controlled Trial

Headache

47, 170-180

DOI: [10.1111/j.1526-4610.2006.00684.x](https://doi.org/10.1111/j.1526-4610.2006.00684.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Stephen D. Silberstein, MD. Neurology Today: an Official Publication of the American Academy of Neurology, 2007, 7, 37-38.	0.0	0
3	Management of medication-overuse headache. Expert Review of Neurotherapeutics, 2007, 7, 1145-1155.	1.4	39
4	Topiramate for migraine prophylaxis. Expert Opinion on Pharmacotherapy, 2007, 8, 2811-2823.	0.9	13
5	Newer aspects of migraine preventive therapies. Drug Development Research, 2007, 68, 315-320.	1.4	1
6	Medication overuse headache: clinical features, pathogenesis and management. Drug Development Research, 2007, 68, 449-460.	1.4	4
8	Migraine and Topiramate Induced Dyspnea. Headache, 2007, 47, 070916230627008-???.	1.8	4
9	The Impact of Topiramate on Health-Related Quality of Life Indicators in Chronic Migraine. Headache, 2007, 47, 1398-1408.	1.8	57
11	Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurological Sciences, 2007, 28, S188-S197.	0.9	32
13	Chronic daily headache: Transformational migraine, chronic migraine, and related disorders. Current Neurology and Neuroscience Reports, 2008, 8, 100-107.	2.0	9
14	Update on the prophylaxis of migraine. Current Treatment Options in Neurology, 2008, 10, 20-29.	0.7	64
15	When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis?. Neurological Sciences, 2008, 29, 55-58.	0.9	26
16	More lessons for the treatment of chronic daily headache. Journal of Headache and Pain, 2008, 9, 3-4.	2.5	2
18	A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurologica Scandinavica, 2008, 118, 301-305.	1.0	59
19	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. Headache, 2008, 48, 799-804.	1.8	17
20	Treatment-Refractory Migraine: The Case for Opioid Therapy. Headache, 2008, 48, 850-854.	1.8	13
21	Epidemiology, Risk Factors, and Treatment of Chronic Migraine: A Focus on Topiramate. Headache, 2008, 48, 1087-1095.	1.8	35
22	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. Headache, 2008, 48, 1399-1405.	1.8	19
23	Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate. CNS Neuroscience and Therapeutics, 2008, 14, 120-142.	1.9	115

#	ARTICLE	IF	CITATIONS
24	Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults. Cephalalgia, 2008, 28, 484-495.	1.8	270
25	How Clinicians can Detect, Prevent and Treat Medication Overuse Headache. Cephalalgia, 2008, 28, 1207-1217.	1.8	36
26	Assessing Functional Impairment During and Between Migraine Attacks. Journal for Nurse Practitioners, 2008, 4, 201-207.	0.4	3
27	Acute bilateral simultaneous angle closure glaucoma after topiramate administration: a case report. Journal of Medical Case Reports, 2008, 2, 1.	0.4	42
28	Treatment of migraine with prophylactic drugs. Expert Opinion on Pharmacotherapy, 2008, 9, 2565-2573.	0.9	49
29	A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clinical Neurology and Neurosurgery, 2008, 110, 979-984.	0.6	59
30	Medication Overuse Headache. CNS Drugs, 2008, 22, 995-1004.	2.7	28
31	Chronic migraine in the population. Neurology, 2008, 71, 559-566.	1.5	434
32	Chronic daily headache. Expert Review of Neurotherapeutics, 2008, 8, 361-384.	1.4	15
35	Topiramate for the Treatment of Chronic Corneal Pain. Cornea, 2008, 27, 124-126.	0.9	1
36	Headache. Current Opinion in Neurology, 2008, 21, 284-287.	1.8	0
37	Therapie der Migräne. , 2008, , .		8
38	Migraine prophylaxis. Medical Journal of Australia, 2008, 189, 283-288.	0.8	13
40	Prophylactic treatment of migraine and migraine clinical variants with topiramate: an update. Therapeutics and Clinical Risk Management, 2009, 5, 661.	0.9	11
41	Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference. Neuropsychiatric Disease and Treatment, 2009, 6, 17.	1.0	26
42	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age. Pediatrics, 2009, 123, 924-934.	1.0	135
43	Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life. Mayo Clinic Proceedings, 2009, 84, 422-435.	1.4	180
44	Dynamic optimization of chronic migraine treatment. Neurology, 2009, 72, S14-20.	1.5	13

#	ARTICLE	IF	CITATIONS
45	A systematic review of adverse events in placebo groups of anti-migraine clinical trials. <i>Pain</i> , 2009, 146, 261-269.	2.0	199
46	Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. <i>Clinical Therapeutics</i> , 2009, 31, 542-559.	1.1	124
47	Advances in the basic and clinical science of migraine. <i>Annals of Neurology</i> , 2009, 65, 491-498.	2.8	123
48	New drugs for migraine. <i>Journal of Headache and Pain</i> , 2009, 10, 395-406.	2.5	30
49	Topiramate in migraine progression. <i>Journal of Headache and Pain</i> , 2009, 10, 419-422.	2.5	14
50	New daily persistent headache in children and adults. <i>Current Pain and Headache Reports</i> , 2009, 13, 47-51.	1.3	29
51	Chronic migraine: Current pathophysiologic concepts as targets for treatment. <i>Current Pain and Headache Reports</i> , 2009, 13, 64-66.	1.3	0
52	Topiramate Treatment of Chronic Migraine: A Randomized, Placebo-Controlled Trial of Quality of Life and Other Efficacy Measures. <i>Headache</i> , 2009, 49, 1153-1162.	1.8	112
53	A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX [®]) and Topiramate (TOPAMAX [®]) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study. <i>Headache</i> , 2009, 49, 1466-1478.	1.8	139
54	EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. <i>European Journal of Neurology</i> , 2009, 16, 968-981.	1.7	649
55	Utility of Topiramate for the Treatment of Patients with Chronic Migraine in the Presence or Absence of Acute Medication Overuse. <i>Cephalalgia</i> , 2009, 29, 1021-1027.	1.8	128
56	Topiramate administration decreases body weight and preserves lean body mass in hemicranic women. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2009, 4, e148-e151.	0.4	3
57	The Face of Chronic Migraine: Epidemiology, Demographics, and Treatment Strategies. <i>Neurologic Clinics</i> , 2009, 27, 467-479.	0.8	20
58	Conceptualizing the relationship between chronic migraine and episodic migraine. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1451-1454.	1.4	16
59	Migraine and Functional Impairment. <i>CNS Drugs</i> , 2009, 23, 1039-1045.	2.7	25
60	Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life. <i>Mayo Clinic Proceedings</i> , 2009, 84, 422-435.	1.4	134
61	Pregabalin in the Treatment of Chronic Migraine. <i>Clinical Neuropharmacology</i> , 2010, 33, 35-39.	0.2	54
63	Pharmacological Management of Migraine Headaches. <i>Nurse Practitioner</i> , 2010, 35, 16-22.	0.2	2

#	ARTICLE	IF	CITATIONS
64	New therapeutic developments in chronic migraine. <i>Current Opinion in Neurology</i> , 2010, 23, 254-258.	1.8	21
65	Contemporary management of migrainous disorders in pregnancy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010, 22, 437-445.	0.9	180
66	Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. <i>Neurological Sciences</i> , 2010, 31, 23-28.	0.9	57
67	Are the current IHS guidelines for migraine drug trials being followed?. <i>Journal of Headache and Pain</i> , 2010, 11, 457-468.	2.5	14
68	New developments and prospects in the treatment of migraine. <i>Douleur Et Analgesie</i> , 2010, 23, 166-174.	0.2	0
69	Current practice and future directions in the prevention and acute management of migraine. <i>Lancet Neurology</i> , The, 2010, 9, 285-298.	4.9	203
70	Topiramate-induced depression in cases using topiramate for migraine prophylaxis. <i>Cephalalgia</i> , 2010, 30, 747-749.	1.8	8
71	Long-term Evolution of Chronic Daily Headache With Medication Overuse in the General Population. <i>Headache</i> , 2010, 50, 981-988.	1.8	33
72	Reversible Hypohidrosis With Topiramate Therapy for Chronic Migraine. <i>Headache</i> , 2010, 50, 672-674.	1.8	10
73	OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-blind, Randomized, Placebo-controlled Phases of the PREEMPT Clinical Program. <i>Headache</i> , 2010, 50, 921-936.	1.8	779
74	Implanted Auriculotemporal Nerve Stimulator for the Treatment of Refractory Chronic Migraine. <i>Headache</i> , 2010, 50, 1064-1069.	1.8	25
76	Defining the Pharmacologically Intractable Headache for Clinical Trials and Clinical Practice. <i>Headache</i> , 2010, 50, 1499-1506.	1.8	42
77	Assessment and Treatment of the Burden of Migraine. <i>Neurologist</i> , 2010, 16, 254-261.	0.4	2
78	OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. <i>Cephalalgia</i> , 2010, 30, 793-803.	1.8	797
79	Arzneiverordnungs-Report 2010. , 2010, , .		41
80	Diagnosis and Management of Chronic Daily Headache. <i>Seminars in Neurology</i> , 2010, 30, 154-166.	0.5	37
82	Role of Antiepileptic Drugs as Preventive Agents for Migraine. <i>CNS Drugs</i> , 2010, 24, 21-33.	2.7	39
84	Cognitive Effects of Topiramate in Migraine Patients Aged 12 Through 17 Years. <i>Pediatric Neurology</i> , 2010, 42, 187-195.	1.0	37

#	ARTICLE	IF	CITATIONS
85	New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. <i>Lancet, The</i> , 2010, 376, 645-655.	6.3	99
86	OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. <i>Cephalalgia</i> , 2010, 30, 804-814.	1.8	795
87	Clinical pharmacology of topiramate in migraine prevention. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1169-1181.	1.5	12
91	Topiramate: Safety and Efficacy of its Use in the Prevention and Treatment of Migraine. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNSD.S4365.	0.7	25
92	Treatment of medication overuse headache - guideline of the EFNS headache panel. <i>European Journal of Neurology</i> , 2011, 18, 1115-1121.	1.7	168
93	Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache. <i>Headache</i> , 2011, 51, 33-51.	1.8	111
94	Treatment Outcomes of Chronic Post-Traumatic Headaches After Mild Head Trauma in US Soldiers: An Observational Study. <i>Headache</i> , 2011, 51, 932-944.	1.8	107
95	Implications of Current Clinical Trials Focused on Medication Overuse and Therapeutic Prophylaxis. <i>Headache</i> , 2011, 51, 93-100.	1.8	0
96	OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program. <i>Headache</i> , 2011, 51, 1358-1373.	1.8	243
97	Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine. <i>Headache</i> , 2011, 51, 1573-1577.	1.8	67
98	Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. <i>Journal of Headache and Pain</i> , 2011, 12, 235-238.	2.5	33
99	Chronic migraine plus medication overuse headache: two entities or not?. <i>Journal of Headache and Pain</i> , 2011, 12, 593-601.	2.5	87
100	Update on Chronic Daily Headache. <i>Current Treatment Options in Neurology</i> , 2011, 13, 41-55.	0.7	33
101	Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?. <i>Internal and Emergency Medicine</i> , 2011, 6, 23-28.	1.0	15
102	OnabotulinumtoxinA: Preventive Treatment for Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2011, 15, 4-7.	1.3	4
103	Treatment of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2011, 15, 64-69.	1.3	43
104	Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. <i>Cephalalgia</i> , 2011, 31, 271-285.	1.8	358
105	Levetiracetam in chronic daily headache: A double-blind, randomised placebo-controlled study. <i>Cephalalgia</i> , 2011, 31, 530-536.	1.8	45

#	ARTICLE	IF	CITATIONS
106	Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. <i>Cephalalgia</i> , 2011, 31, 1343-1358.	1.8	76
107	A trans-cultural comparison of the organisation of care at headache centres world-wide. <i>Cephalalgia</i> , 2011, 31, 316-330.	1.8	10
108	Acupuncture versus topiramate in chronic migraine prophylaxis: A randomized clinical trial. <i>Cephalalgia</i> , 2011, 31, 1510-1521.	1.8	102
109	Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. <i>Cephalalgia</i> , 2011, 31, 18-30.	1.8	53
110	Needling the pain and comforting the brain: Acupuncture in the treatment of chronic migraine. <i>Cephalalgia</i> , 2011, 31, 1507-1509.	1.8	9
111	The Cleveland Clinic Manual of Headache Therapy. , 2011, , .		6
112	Botox for chronic migraine. <i>Drug and Therapeutics Bulletin</i> , 2011, 49, 22-24.	0.3	3
113	Chronic daily headaches. <i>Annals of Indian Academy of Neurology</i> , 2012, 15, 40.	0.2	11
114	Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. <i>Neurology</i> , 2012, 78, 976-984.	1.5	76
115	Suppressive effect of chronic peroral topiramate on potassium-induced cortical spreading depression in rats. <i>Cephalalgia</i> , 2012, 32, 518-527.	1.8	21
116	Medication-Overuse Headache. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2012, 18, 807-822.	0.4	40
117	Acute and Preventive Treatment of Migraine. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2012, 18, 764-782.	0.4	27
119	A Comparative Study of the Effects of Low-Dose Topiramate Versus Sodium Valproate in Migraine Prophylaxis. <i>International Journal of Neuroscience</i> , 2012, 122, 60-68.	0.8	30
120	Detoxification for medication overuse headache is not necessary. <i>Cephalalgia</i> , 2012, 32, 423-427.	1.8	49
121	Occipital nerve stimulation for chronic migraine: Already advised?. <i>Cephalalgia</i> , 2012, 32, 1163-1164.	1.8	8
122	Prevention and management of medication overuse headache. <i>Current Opinion in Neurology</i> , 2012, 25, 290-295.	1.8	38
124	Central Nervous System Acting Drugs in Treatment of Migraine Headache. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2012, 12, 158-172.	0.5	9
125	Antiepileptic drugs. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 108, 723-739.	1.0	13

#	ARTICLE	IF	CITATIONS
126	Topiramate and cognitive impairment: evidence and clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2012, 3, 279-289.	1.0	54
128	A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss. <i>Combination Products in Therapy</i> , 2012, 2, 1.	1.1	5
129	Understanding Migraine through the Lens of Maladaptive Stress Responses: A Model Disease of Allostatic Load. <i>Neuron</i> , 2012, 73, 219-234.	3.8	282
130	Preventive Treatment of Migraine. <i>Headache</i> , 2012, 52, 65-69.	1.8	10
131	OnabotulinumtoxinA (BOTOX®). <i>Drugs</i> , 2012, 72, 825-845.	4.9	34
132	Chronic migraine—classification, characteristics and treatment. <i>Nature Reviews Neurology</i> , 2012, 8, 162-171.	4.9	130
133	Emerging treatment for chronic migraine and refractory chronic migraine. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 393-406.	1.0	63
134	Bilateral Acute Angle-Closure Glaucoma in a Migraine Patient Receiving Topiramate: A Case Report. <i>Journal of Emergency Medicine</i> , 2012, 43, e89-e91.	0.3	15
138	As a rare cause of drug-induced cough: topiramate. <i>Acta Neurologica Belgica</i> , 2012, 112, 217-220.	0.5	5
139	Rizatriptan for Treatment of Acute Migraine in Patients Taking Topiramate for Migraine Prophylaxis. <i>Headache</i> , 2012, 52, 57-67.	1.8	8
140	OnabotulinumtoxinA for Chronic Migraine. <i>Headache</i> , 2012, 52, 142-148.	1.8	7
141	Advanced Interventions for Headache. <i>Headache</i> , 2012, 52, 50-54.	1.8	5
142	Biofeedback Therapy for Pediatric Headache: Factors Associated With Response. <i>Headache</i> , 2012, 52, 1377-1386.	1.8	50
143	CaV2.1 voltage activated calcium channels and synaptic transmission in familial hemiplegic migraine pathogenesis. <i>Journal of Physiology (Paris)</i> , 2012, 106, 12-22.	2.1	14
144	Defining the Differences Between Episodic Migraine and Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2012, 16, 86-92.	1.3	211
145	OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. <i>Journal of the Neurological Sciences</i> , 2013, 331, 48-56.	0.3	168
146	Medication Overuse Headache: History, Features, Prevention and Management Strategies. <i>CNS Drugs</i> , 2013, 27, 867-877.	2.7	40
147	Opioids can be useful in the treatment of headache. <i>Neurological Sciences</i> , 2013, 34, 119-124.	0.9	9

#	ARTICLE	IF	CITATIONS
149	Migraine-like Episodic Pain Behavior in a Dog: Can Dogs Suffer from Migraines?. Journal of Veterinary Internal Medicine, 2013, 27, 1034-1040.	0.6	10
150	Topiramate: Safety in migraine patients. Journal of Young Pharmacists, 2013, 5, 30-31.	0.1	1
151	Medication Overuse Headaches. Medical Clinics of North America, 2013, 97, 337-352.	1.1	31
152	Preventive Pharmacologic Treatments for Episodic Migraine in Adults. Journal of General Internal Medicine, 2013, 28, 1225-1237.	1.3	76
153	Chronic migraine. Revue Neurologique, 2013, 169, 419-426.	0.6	3
155	The pathophysiological and pharmacological basis of current drug treatment of migraine headache. Expert Review of Clinical Pharmacology, 2013, 6, 271-288.	1.3	18
156	Predicting Prognostic Factors in a Randomized Controlled Trial of Acupuncture Versus Topiramate Treatment in Patients With Chronic Migraine. Clinical Journal of Pain, 2013, 29, 982-987.	0.8	15
157	Topiramate is likely to act outside of the trigeminocervical complex. Cephalalgia, 2013, 33, 291-300.	1.8	14
158	Cognitive Behavioral Therapy Plus Amitriptyline for Chronic Migraine in Children and Adolescents. JAMA - Journal of the American Medical Association, 2013, 310, 2622.	3.8	229
159	Migrende Profilaktik Tedavi. Noropsikiyatri Arsivi, 2013, 50, 30-35.	0.7	5
161	Novel Approaches in Migraine Treatment. , 2013, , .		2
162	Latin American consensus on guidelines for chronic migraine treatment. Arquivos De Neuro-Psiquiatria, 2013, 71, 478-486.	0.3	25
163	Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study. Arquivos De Neuro-Psiquiatria, 2014, 72, 851-855.	0.3	58
164	Chronic Daily Headache in Korea: Prevalence, Clinical Characteristics, Medical Consultation and		

#	ARTICLE	IF	CITATIONS
170	Analysis of the duration of migraine prophylaxis. <i>Journal of the Neurological Sciences</i> , 2014, 337, 38-41.	0.3	8
171	Topiramate in the Treatment of Chronic Migraine. <i>Neuroscience and Behavioral Physiology</i> , 2014, 44, 310-314.	0.2	1
175	Treatment of PTSD and Chronic Daily Headache. <i>Current Treatment Options in Neurology</i> , 2014, 16, 312.	0.7	4
176	Medication Overuse Headache. <i>Headache</i> , 2014, 54, 1251-1257.	1.8	47
177	Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. <i>European Journal of Neurology</i> , 2014, 21, 851-859.	1.7	47
178	Safety of topiramate for treating migraines. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1241-1247.	1.0	17
179	Glutamate Receptor Antagonists in the Management of Migraine. <i>Drugs</i> , 2014, 74, 1165-1176.	4.9	40
180	Chronic migraine. <i>BMJ, The</i> , 2014, 348, g1416-g1416.	3.0	187
181	Efficacy and mechanism of anticonvulsant drugs in migraine. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 191-201.	1.3	39
182	The Cleveland Clinic Manual of Headache Therapy. , 2014, , .		4
183	Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 10-15.	0.6	24
184	Medication overuse headache—seeking a management consensus. <i>Nature Reviews Neurology</i> , 2014, 10, 309-310.	4.9	4
185	A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. <i>Cephalalgia</i> , 2014, 34, 645-655.	1.8	108
186	Sodium channel antagonists for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1697-1706.	0.9	20
189	Beyond Neural Cubism. <i>Academic Medicine</i> , 2015, 90, 581-586.	0.8	14
191	A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. <i>PLoS ONE</i> , 2015, 10, e0130733.	1.1	198
192	Evidence-Based Treatments for Adults with Migraine. <i>Pain Research and Treatment</i> , 2015, 2015, 1-13.	1.7	17
193	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Duliang Soft Capsule in Patients with Chronic Daily Headache. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	6

#	ARTICLE	IF	CITATIONS
194	Best Practices for Patients With Chronic Migraine. Mayo Clinic Proceedings, 2015, 90, 408-414.	1.4	33
195	Chronic Daily Headache. Physical Medicine and Rehabilitation Clinics of North America, 2015, 26, 375-389.	0.7	9
196	The diagnosis and treatment of chronic migraine. Therapeutic Advances in Chronic Disease, 2015, 6, 115-123.	1.1	119
197	Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial. Journal of Headache and Pain, 2015, 16, 543.	2.5	212
198	Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache, 2015, 55, 99-102.	1.8	1
199	Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache, 2015, 55, 103-122.	1.8	227
200	Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. Journal of Pain, 2015, 16, 164-175.	0.7	49
201	The Risk and Management of Kidney Stones From the Use of Topiramate and Zonisamide in Migraine and Idiopathic Intracranial Hypertension. Headache, 2015, 55, 161-166.	1.8	19
202	OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain, 2015, 156, 820-824.	2.0	136
203	Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurology, 2015, 15, 100.	0.8	25
204	A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine. Current Pain and Headache Reports, 2015, 19, 49.	1.3	17
205	Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?. Cephalalgia, 2015, 35, 864-868.	1.8	89
206	Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clinical Medicine, 2015, 15, 344-350.	0.8	58
207	Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management. Pain Practice, 2015, 15, 688-692.	0.9	9
208	Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society. Acta Neurologica Belgica, 2015, 115, 1-17.	0.5	15
210	Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology, 2016, 12, 455-464.	4.9	391
211	Randomized Controlled Pilot Trial of Behavioral Insomnia Treatment for Chronic Migraine With Comorbid Insomnia. Headache, 2016, 56, 276-291.	1.8	80
212	Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year. Journal of Headache and Pain, 2016, 17, 112.	2.5	46

#	ARTICLE	IF	CITATIONS
213	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. <i>Journal of Headache and Pain</i> , 2016, 17, 48.	2.5	49
214	39 Literatur. , 2016, , .		0
215	Medication-overuse headache: risk factors, pathophysiology and management. <i>Nature Reviews Neurology</i> , 2016, 12, 575-583.	4.9	197
216	Botulinum toxin. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2016, 29, 1-4.	0.1	2
217	Chronic Daily Headache: Mechanisms and Principles of Management. <i>Current Pain and Headache Reports</i> , 2016, 20, 10.	1.3	13
218	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 399-406.	1.5	29
219	Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients. <i>Neurological Sciences</i> , 2016, 37, 585-589.	0.9	12
220	Update on the Pharmacological Treatment of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2016, 20, 6.	1.3	32
221	Outcome of Chronic Daily Headache or Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2016, 20, 2.	1.3	8
223	Treatment of medication-overuse headache: A systematic review. <i>Cephalalgia</i> , 2016, 36, 371-386.	1.8	148
224	Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. <i>Cephalalgia</i> , 2017, 37, 356-364.	1.8	27
225	Short-term effects of greater occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-controlled clinical trial. <i>Cephalalgia</i> , 2017, 37, 864-872.	1.8	90
226	Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 476-483.	1.0	32
227	Which Matters More? A Retrospective Cohort Study of Headache Characteristics and Diagnosis Type in Soldiers with mTBI/Concussion. <i>Headache</i> , 2017, 57, 719-728.	1.8	16
228	Spotlight on Anti-€CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 534-547.	0.8	56
229	Treatment Update of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2017, 21, 26.	1.3	37
230	Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 425-434.	4.9	589
231	Topiramate in Migraine Prevention: A 2016 Perspective. <i>Headache</i> , 2017, 57, 165-178.	1.8	89

#	ARTICLE	IF	CITATIONS
232	Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. <i>Journal of Headache and Pain</i> , 2017, 18, 26.	2.5	29
233	Intranasally administered IGF-1 inhibits spreading depression in vivo. <i>Brain Research</i> , 2017, 1677, 47-57.	1.1	16
234	Blocking CGRP in migraine patients – a review of pros and cons. <i>Journal of Headache and Pain</i> , 2017, 18, 96.	2.5	217
235	Preventing and treating medication overuse headache. <i>Pain Reports</i> , 2017, 2, e612.	1.4	22
236	Sleep in Patients with Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2017, 21, 39.	1.3	45
237	Medication Overuse Headache in the Emergency Department. , 0, , 99-109.		0
238	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. <i>Journal of Headache and Pain</i> , 2017, 18, 66.	2.5	27
239	The supraorbital region revisited: An anatomic exploration of the neuro-vascular bundle with regard to frontal migraine headache. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 1171-1180.	0.5	15
240	Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. <i>Cephalalgia</i> , 2017, 37, 470-485.	1.8	256
241	Botulinum toxin in the management of chronic migraine: clinical evidence and experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 127-135.	1.5	59
242	PFO and Migraine. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2775-2777.	1.2	5
243	Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. <i>Journal of Headache and Pain</i> , 2017, 18, 93.	2.5	20
244	The efficacy of topiramate in alcohol dependence therapy – current research and prospects of use. <i>Alkoholizm I Narkomania</i> , 2017, 30, 205-222.	0.3	0
245	Topographic methods to expose the exiting points of supratrochlear, supraorbital, and zygomaticotemporal nerves. <i>Turkish Journal of Medical Sciences</i> , 2017, 47, 1861-1865.	0.4	2
246	OnabotulinumtoxinA for Chronic Migraine. <i>Headache</i> , 2017, 57, E10-E16.	1.8	3
247	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832.	1.8	245
248	Systematic review of the pharmacological agents that have been tested against spreading depolarizations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1149-1179.	2.4	37
249	A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine. <i>Headache</i> , 2018, 58, 48-59.	1.8	43

#	ARTICLE	IF	CITATIONS
250	Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. <i>European Journal of Neurology</i> , 2018, 25, 1069.	1.7	39
251	CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. <i>Current Pain and Headache Reports</i> , 2018, 22, 38.	1.3	25
252	Fundamentals of Pain Medicine. , 2018, , .		5
253	The Management of Pain States: Pharmacologic Treatment. , 2018, , 53-60.		0
254	Cyclic vomiting syndrome: epidemiology, diagnosis, and treatment. <i>Clinical Autonomic Research</i> , 2018, 28, 203-209.	1.4	28
255	Treatment of the Patient with Refractory Headache. <i>Current Pain and Headache Reports</i> , 2018, 22, 23.	1.3	3
256	Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. <i>Cephalalgia</i> , 2018, 38, 225-236.	1.8	77
257	OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. <i>European Journal of Neurology</i> , 2018, 25, 411-416.	1.7	65
258	Galcanezumab in chronic migraine. <i>Neurology</i> , 2018, 91, e2211-e2221.	1.5	399
260	Comprehensive review and update on chronic migraine. <i>Journal of the Korean Medical Association</i> , 2018, 61, 314.	0.1	1
261	From LBR-101 to Fremanezumab for Migraine. <i>CNS Drugs</i> , 2018, 32, 1025-1037.	2.7	13
262	Chronic Migraine – Evolution of the Concept and Clinical Implications. <i>Headache</i> , 2018, 58, 1495-1500.	1.8	13
264	Animal Models of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2018, 22, 44.	1.3	21
265	Botulinum toxins for the prevention of migraine in adults. <i>The Cochrane Library</i> , 2018, 2018, CD011616.	1.5	53
267	Qualitative Change in Migraine Prevention?. <i>Headache</i> , 2018, 58, 1092-1095.	1.8	7
268	Diagnosis and Treatment of Migraine: Recommendations of Russian Experts. <i>Neuroscience and Behavioral Physiology</i> , 2018, 48, 621-635.	0.2	1
269	Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> , 2018, 38, 1611-1621.	1.8	104
270	Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. <i>Journal of Headache and Pain</i> , 2018, 19, 73.	2.5	25

#	ARTICLE	IF	CITATIONS
271	Efficacy and safety of external trigeminal neurostimulation in the prevention of chronic migraine: An open-label trial. <i>Cephalalgia Reports</i> , 2019, 2, 251581631985662.	0.2	6
272	Consensus of the Brazilian Headache Society on the treatment of chronic migraine. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 509-520.	0.3	16
273	An Update on Cognitive Therapy for the Management of Chronic Pain: a Comprehensive Review. <i>Current Pain and Headache Reports</i> , 2019, 23, 57.	1.3	27
274	Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. <i>Clinical Drug Investigation</i> , 2019, 39, 979-990.	1.1	24
275	Medication Overuse and Medication Overuse Headache: Risk Factors, Comorbidities, Associated Burdens and Nonpharmacologic and Pharmacologic Treatment Approaches. <i>Current Pain and Headache Reports</i> , 2019, 23, 60.	1.3	16
276	Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine. <i>Headache</i> , 2019, 59, 1743-1752.	1.8	32
277	FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. <i>Headache</i> , 2019, 59, 1700-1713.	1.8	55
278	Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. <i>Journal of Headache and Pain</i> , 2019, 20, 98.	2.5	64
279	OnabotulinumtoxinA in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience. <i>Headache</i> , 2019, 59, 1300-1309.	1.8	16
280	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. <i>Journal of Headache and Pain</i> , 2019, 20, 92.	2.5	116
281	Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients. <i>Pain Medicine</i> , 2019, 20, 1815-1821.	0.9	16
283	Erenumab in chronic migraine with medication overuse. <i>Neurology</i> , 2019, 92, e2309-e2320.	1.5	163
284	Calcitonin Gene-Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class. <i>Headache</i> , 2019, 59, 951-970.	1.8	103
285	Development of an education and self-management intervention for chronic headache – CHES trial (Chronic Headache Education and Self-management Study). <i>Journal of Headache and Pain</i> , 2019, 20, 28.	2.5	19
286	Prediction of patient's response to OnabotulinumtoxinA treatment for migraine. <i>Heliyon</i> , 2019, 5, e01043.	1.4	15
287	Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention. <i>Annals of Pharmacotherapy</i> , 2019, 53, 933-939.	0.9	17
288	Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials. <i>Headache</i> , 2019, 59, 834-847.	1.8	31
289	Treating Chronic Migraine With Neuromodulation: The Role of Neurophysiological Abnormalities and Maladaptive Plasticity. <i>Frontiers in Pharmacology</i> , 2019, 10, 32.	1.6	22

#	ARTICLE	IF	CITATIONS
290	Real world preventative drug management of migraine among Spanish neurologists. <i>Journal of Headache and Pain</i> , 2019, 20, 19.	2.5	16
291	Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. <i>Journal of Headache and Pain</i> , 2019, 20, 12.	2.5	16
292	MIGRAÑA, UN DESAFÍO PARA EL MÉDICO NO ESPECIALISTA. <i>Revista Médica Clínica Las Condes</i> , 2019, 30, 407-413.	0.2	0
293	Pharmacologic Approaches to CDH: Evidence and Outcomes. , 2019, , 217-230.		0
294	Neurostimulation in the Management of Chronic Migraine. , 2019, , 335-344.		0
295	Chronic Migraine: Epidemiology, Mechanisms, and Treatment. , 2019, , 37-62.		1
296	Medication Overuse in Chronic Daily Headache. , 2019, , 195-206.		0
297	Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. <i>Cephalalgia</i> , 2019, 39, 608-616.	1.8	17
298	OnabotulinumtoxinA injection in the treatment of chronic migraine. <i>Progress in Brain Research</i> , 2020, 255, 171-206.	0.9	6
299	Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272095993.	1.0	14
300	Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272095993.	1.0	4
301	Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis. <i>Headache</i> , 2020, 60, 1542-1557.	1.8	32
302	Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants. <i>Progress in Brain Research</i> , 2020, 255, 143-170.	0.9	39
303	Medication Overuse Withdrawal in Children and Adolescents Does Not Always Improve Headache: A Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2020, 11, 823.	1.1	5
304	Migraine. <i>New England Journal of Medicine</i> , 2020, 383, 1866-1876.	13.9	376
305	European Academy of Neurology guideline on the management of medication-overuse headache. <i>European Journal of Neurology</i> , 2020, 27, 1102-1116.	1.7	69
306	Update in migraine preventive treatment. <i>Progress in Brain Research</i> , 2020, 255, 1-27.	0.9	4
307	Digital Cognitive Behavioral Therapy for Insomnia in Women With Chronic Migraines. <i>Headache</i> , 2020, 60, 902-915.	1.8	24

#	ARTICLE	IF	CITATIONS
308	Reduction in Migraine and Headache Frequency and Intensity With Combined Antioxidant Prophylaxis (N-acetylcysteine, Vitamin E, and Vitamin C): A Randomized Sham-Controlled Pilot Study. <i>Pain Practice</i> , 2020, 20, 737-747.	0.9	16
309	Documento de revisión y actualización de la cefalea por uso excesivo de medicación (CUEM). <i>Neurología</i> , 2021, 36, 229-240.	0.3	5
310	Reversion from chronic migraine to episodic migraine: A new outcome measure. <i>Cephalalgia</i> , 2021, 41, 3-5.	1.8	0
311	Chronic Migraine: An Update on Diagnosis and Management. <i>Neurology India</i> , 2021, 69, 67.	0.2	3
312	Identification of predictors of response to Erenumab in a cohort of patients with migraine. <i>Cephalalgia Reports</i> , 2021, 4, 251581632110266.	0.2	10
313	Comprehensive management of adults with chronic migraine: Clinical practice guidelines in Mexico. <i>Cephalalgia Reports</i> , 2021, 4, 251581632110339.	0.2	0
315	Topiramate, acupuncture, and BoNT-A for chronic migraine: a network meta-analysis. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 558-568.	1.0	6
316	Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. <i>Cephalalgia</i> , 2021, 41, 851-864.	1.8	53
317	Migraine: integrated approaches to clinical management and emerging treatments. <i>Lancet</i> , The, 2021, 397, 1505-1518.	6.3	139
318	Document of revision and updating of medication overuse headache (MOH). <i>Neurología (English)</i> Tj ETQq1 1 0.784314 rgBT /Overlook	0.2	1
319	The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update. <i>CNS Drugs</i> , 2021, 35, 545-565.	2.7	25
320	Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). <i>Journal of Headache and Pain</i> , 2021, 22, 35.	2.5	82
321	Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis. <i>Pain</i> , 2022, 163, 415-424.	2.0	16
322	Safety and tolerability of preventive treatment options for chronic migraine. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1523-1533.	1.0	10
323	OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-15.	1.0	10
324	Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. <i>Frontiers in Pain Research</i> , 2021, 2, 705276.	0.9	31
325	TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. <i>Cephalalgia</i> , 2022, 42, 396-408.	1.8	11
326	Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials. <i>Neurotherapeutics</i> , 2021, 18, 2639-2650.	2.1	17

#	ARTICLE	IF	CITATIONS
327	Relationships between migraine and epilepsy: Pathophysiological mechanisms and clinical implications. <i>Revue Neurologique</i> , 2021, 177, 791-800.	0.6	12
328	Advances in topiramate as prophylactic treatment for migraine. <i>Brain and Behavior</i> , 2021, 11, e2290.	1.0	6
330	Comparison of 3 Treatment Strategies for Medication Overuse Headache. <i>JAMA Neurology</i> , 2020, 77, 1069.	4.5	71
331	Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. <i>Neurological Sciences</i> , 2017, 38, 201-206.	0.9	50
332	Headache and Other Craniofacial Pain. , 2012, , 1703-1744.		7
334	Efficacy and Tolerability of Pregabalin Versus Topiramate in the Prophylaxis of Chronic Daily Headache With Analgesic Overuse. <i>Clinical Neuropharmacology</i> , 2011, 34, 74-78.	0.2	13
335	Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. <i>Clinical and Translational Neuroscience</i> , 2019, 3, 2514183X1882337.	0.4	41
336	Risk Factors for and Management of Medication-Overuse Headache. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2015, 21, 1118-1131.	0.4	10
337	Topiramate modulates trigeminal pain processing in thalamo-cortical networks in humans after single dose administration. <i>PLoS ONE</i> , 2017, 12, e0184406.	1.1	26
340	The effectiveness of anticonvulsants in psychiatric disorders. <i>Dialogues in Clinical Neuroscience</i> , 2008, 10, 77-89.	1.8	32
342	Assessment of the Middle Dose of Topiramate in Comparison with Sodium Valproate for Migraine Prophylaxis: A Randomized-Double-Blind Study. <i>International Journal of Pharmacology</i> , 2010, 6, 670-675.	0.1	6
343	Breaking the cycle of medication overuse headache. <i>Cleveland Clinic Journal of Medicine</i> , 2010, 77, 236-242.	0.6	44
344	Anterior segment optical coherence tomography documentation of a case of topiramate induced acute angle closure. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 619.	0.5	15
345	Cefalea crÃ³nica diaria con Abuso de AnalgÃ©sicos. <i>Revista ClÃnica De Medicina De Familia</i> , 2009, 2, .	0.1	5
346	Management of migraine headaches in a chronic pain patient: A case report. <i>Mental Health Clinician</i> , 2016, 6, 154-158.	0.5	2
347	Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110501.	0.7	2
348	CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. <i>Journal of Headache and Pain</i> , 2021, 22, 128.	2.5	66
350	MigrÃnemittel. , 2008, , 691-700.		0

#	ARTICLE	IF	CITATIONS
354	Cefalee. , 2009, , 217-248.		1
355	Significance of Glutamate Receptor, Especially AMPA/KA Receptors, in Epilepsy and Antiepileptic Effects of Novel Antiepileptic Drug, Topiramate. Journal of the Japan Epilepsy Society, 2009, 26, 419-439.	0.1	0
356	Recent advances in the pharmacological management of migraine. F1000 Medicine Reports, 2009, 1, .	2.9	0
359	MigrÃnemittel. , 2010, , 711-721.		0
362	Medical Interventions for Migraine That Has Become Difficult to Treat. , 2011, , 423-434.		0
363	MigrÃ±a con y sin aura. Tratamiento. , 2011, , 83-106.		1
365	MigrÃ±a crÃ³nica. , 2011, , 143-165.		0
373	IncobotulinumtoxinA (Xeomin®) and OnabotulinumtoxinA (Botox®) for Chronic Migraine Headache: Experience with Higher Doses and Changes to the Injection Technique. Journal of Neurological Disorders, 2014, 02, .	0.1	1
375	Medical Treatment of Refractory Daily Headaches, Including Interdisciplinary Management. , 2014, , 213-225.		0
377	Drug Treatment for Chronic Migraine. Headache, 2016, , 81-87.	0.2	0
378	Galcanezumab in the prophylaxis of migraine. Pharmacotherapy in Psychiatry and Neurology, 2020, 36, 59-66.	0.1	0
379	Chronic Migraine. , 0, , .		0
380	Chronic Migraine in Adolescence. , 0, , .		1
381	Medication Overuse Headache. , 0, , .		0
383	Electrophysiological basis for antiepileptic drugs in migraine prevention. Progress in Brain Research, 2020, 255, 69-97.	0.9	4
384	Opioid Alternative Medication and Clinical Dilemmas. , 2020, , 679-702.		0
385	Anti-convulsant Drugs: Differential Indications â€œ Neuropathic Pain and Migraine. , 2020, , 1-20.		1
386	MigrÃnemittel. , 2008, , 695-704.		0

#	ARTICLE	IF	CITATIONS
388	The pharmacological management of migraine, part 2: preventative therapy. P and T, 2008, 33, 480-7.	1.0	5
389	Case reports on two patients with episodic vertigo, fluctuating hearing loss and migraine responding to prophylactic drugs for migraine. Menière's disease or migraine-associated vertigo?. Acta Otorhinolaryngologica Italica, 2010, 30, 217.	0.7	15
390	Meta-analysis of efficacy of topiramate in migraine prophylaxis. Neural Regeneration Research, 2012, 7, 1806-11.	1.6	3
391	Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. European Journal of Neurology, 2022, 29, 1198-1208.	1.7	43
392	Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open, 2021, 11, e043242.	0.8	18
393	Knowledge, Attitudes, and Management of General Practitioners of the Hospital Districts of Ouagadougou about Migraine (Burkina Faso). Pain Research and Management, 2021, 2021, 1-8.	0.7	1
395	Clinical guidelines "Migraine". Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 4.	0.1	14
396	OUP accepted manuscript. Journal of Pediatric Psychology, 2022, 47, 388-390.	1.1	1
397	Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. Acta Neurologica Scandinavica, 2022, 145, 676-683.	1.0	12
398	Evaluation and treatment of medication-overuse headache: Russian experts'™ guidelines. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 4-13.	0.2	16
399	Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments. Current Pain and Headache Reports, 2022, 26, 347-355.	1.3	14
400	Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial. Cephalalgia, 2022, 42, 859-871.	1.8	8
401	Long-term prophylactic efficacy of transcranial direct current stimulation in chronic migraine. A randomised, patient-assessor blinded, sham-controlled trial. Brain Stimulation, 2022, 15, 441-453.	0.7	9
402	A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine. Clinical Neurology and Neurosurgery, 2022, 215, 107200.	0.6	6
403	Interrelationships between migraine over the counter (OTC) painkillers and hypertensive disorders of pregnancy. Medicine (United States), 2021, 100, e28049.	0.4	0
404	Outcomes That Matter to Adolescents With Continuous Headache Due to Chronic Migraine and Their Parents. Neurology, 2022, 98, .	1.5	4
405	Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. European Journal of Neurology, 2022, 29, 2473-2480.	1.7	9
406	Paroxysmal headaches. , 0, , 45-55.		0

#	ARTICLE	IF	CITATIONS
407	Pharmacogenetics in Primary Headache Disorders. <i>Frontiers in Pharmacology</i> , 2021, 12, 820214.	1.6	7
409	CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies. <i>Current Pain and Headache Reports</i> , 2022, 26, 543-554.	1.3	6
411	Repeated inflammatory dural stimulation-induced cephalic allodynia causes alteration of gut microbial composition in rats. <i>Journal of Headache and Pain</i> , 2022, 23, .	2.5	3
412	Course of Preexisting Migraine Following Spontaneous Subarachnoid Hemorrhage. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
414	Preventive Treatment of Migraine. <i>Seminars in Neurology</i> , 0, , .	0.5	0
415	Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. <i>Neurological Research and Practice</i> , 2022, 4, .	1.0	10
416	Headache in the Pediatric Population: Focus on Migraine. <i>Seminars in Neurology</i> , 2022, 42, 479-488.	0.5	0
417	Chronic Migraine. <i>Neurologic Clinics</i> , 2023, 41, 141-159.	0.8	5
418	Anti-convulsant Drugs: Differential Indications “Neuropathic Pain and Migraine. , 2022, , 3473-3492.		0
419	Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of <sc>CGRP</sc> antibodies? A narrative review. <i>Headache</i> , 2022, 62, 1264-1271.	1.8	3
420	Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study. <i>Toxins</i> , 2022, 14, 850.	1.5	2
422	Antiseizure Medications for the Prophylaxis of Migraine during the Anti- CGRP Drugs Era. <i>Current Neuropharmacology</i> , 2023, 21, 1767-1785.	1.4	3
423	Intensive Mindfulness Meditation Reduces Frequency and Burden of Migraine: An Unblinded Single-Arm Trial. <i>Mindfulness</i> , 0, , .	1.6	0
424	Medication overuse headache. <i>Nature Reviews Disease Primers</i> , 2023, 9, .	18.1	23
437	Chronic migraine and medication overuse. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 187-200.	1.0	1
442	Evidence-based preventive treatment of migraine. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 219-241.	1.0	0
443	OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 87-106.	1.0	0